What is the right moment for noninvasive ventilation in amyotrophic lateral sclerosis?
amyotrophic lateral sclerosis
noninvasive ventilation
pulmonary function
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
04
2019
accepted:
08
09
2019
medline:
8
12
2019
entrez:
10
4
2023
pubmed:
8
12
2019
Statut:
epublish
Résumé
The most common cause of death in patients with amyotrophic lateral sclerosis (ALS) is respiratory failure, often in the period of 2-5 years, with a small percentage of patients surviving up to 10 years or more. The aim of the study was to evaluate the significance of pulmonary function tests in prediction of mortality and definition of indications for noninvasive mechanical ventilation (NIMV). This retrospective-prospective study was performed at the Clinic of Pulmonology, Clinical Centre of Serbia in the period from January 2015 to December 2017. Patients with diagnosis of ALS established according to El Escorial criteria were included. The study included 76 patients with ALS, 50 (65.85%) with spinal and 26 (34.2%) with bulbar form of disease. Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV Our study points to the significance of timely application and early start of NIMV in patients with ALS as an important approach to defer functional impairment, which would mean that the criteria, in our country, for application of these devices must be changed, not only regarding the value of current functional diagnostic tests used in everyday practice in patients with ALS but also in regard to the introduction of new diagnostic tests, such as sniff nasal inspiratory pressure and/or polysomnographic testing.
Identifiants
pubmed: 37034525
doi: 10.5114/aoms.2019.90465
pii: 112212
pmc: PMC10074320
doi:
Types de publication
Journal Article
Langues
eng
Pagination
337-342Informations de copyright
Copyright: © 2019 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Neurology. 2002 Jul 9;59(1):99-103
pubmed: 12105314
Arch Neurol. 2009 Jun;66(6):758-61
pubmed: 19506136
Respir Care. 2013 Sep;58(9):1555-8
pubmed: 23981590
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330
pubmed: 29566571
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Muscle Nerve. 2002 May;25(5):709-714
pubmed: 11994965
Lancet Neurol. 2018 May;17(5):423-433
pubmed: 29598923
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):7-11
pubmed: 28799809
Arch Neurol. 1994 Jan;51(1):17-23
pubmed: 8274106
Chest. 2002 Feb;121(2):436-42
pubmed: 11834654
J Neurol. 2015 Jun;262(6):1447-54
pubmed: 25860344
Am J Respir Crit Care Med. 2017 Jan 1;195(1):86-95
pubmed: 27494149
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1678-83
pubmed: 7952632
J Neurol. 2015 Mar;262(3):593-603
pubmed: 25522696
Brain. 2001 Oct;124(Pt 10):2000-13
pubmed: 11571218
J Biomed Inform. 2015 Dec;58:133-144
pubmed: 26455265
Respirology. 2011 Jul;16(5):869
pubmed: 21545374
Neurology. 2006 Jan 24;66(2):265-7
pubmed: 16434671
Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Dec;5(4):208-12
pubmed: 15799548
Muscle Nerve. 1999 Nov;22(11):1571-5
pubmed: 10514236
Am J Respir Crit Care Med. 2005 Feb 1;171(3):269-74
pubmed: 15516537
JAMA Neurol. 2018 Jan 1;75(1):58-64
pubmed: 29181534
J Clin Sleep Med. 2015 Apr 15;11(5):559-66
pubmed: 25766713
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Thorax. 1996 Dec;51(12):1239-42
pubmed: 8994522
J Neurol Sci. 1998 Oct;160 Suppl 1:S37-41
pubmed: 9851647
Orphanet J Rare Dis. 2009 Feb 03;4:3
pubmed: 19192301
Eur J Neurol. 2013 Dec;20(12):1524-30
pubmed: 23398243
Eur Respir J. 2010 Jul;36(1):12-9
pubmed: 20595163
Thorax. 1995 Apr;50(4):371-5
pubmed: 7785009
Respir Care. 2009 Oct;54(10):1348-59
pubmed: 19796415